VITEK 2 GRAM-POSITIVE ANTIMICROBIAL SUSCEPTIBILITY TEST AST-P586 TEST KIT
Report
- Report Number
- 1950204-2015-00092
- Event Type
- Malfunction
- Date Received
- November 5, 2015
- Report Date
- November 4, 2015
- Manufacturer
- BIOMERIEUX, INC
- Product Code
- LON
- PMA / PMN Number
- K113783
- Product Problem
- Yes
- Report Source
- Manufacturer report
- Reporter Location
- IT
- Reporter Occupation
- HEALTH PROFESSIONAL
Narratives
DEVICE NOT RETURNED TO MANUFACTURER.
THE CUSTOMER DID NOT COMPLY WITH BIOMÉRIEUX'S REQUEST FOR SUBMITTAL OF THE ATCC® 29212 TM QC STRAIN, LAB REPORTS OR RAW DATA. BIOMÉRIEUX INTERNAL INVESTIGATION WAS CONDUCTED USING BIOMÉRIEUX'S INTERNAL ATCC® 29212 QC STRAIN, TWO CARDS FROM THE CUSTOMER AST-P586 LOT AND TWO CARDS EACH FROM TWO RANDOM LOTS. ALL AST-P586 CARDS TESTED OBTAINED ACCEPTABLE QC RESULTS FOR BENZYLPENICILLIN (MIC=2, RANGE IS 1 - 4) AND QUINUDALFOPRISTIN (MIC=8, RANGE IS 1 - 8). EVALUATION OF THE MANUFACTURING QC RECORDS FOR THE LOT IN QUESTION INDICATED THE LOT PASSED QC TESTING AND THERE WERE NO ISSUES WITH BENZYLPENICILLIN AND QUINUDALFOPRISTIN ON INITIAL PERFORMANCE TESTING. THE AST-P586 TEST KITS ARE PERFORMING IN ACCORDANCE WITH SPECIFICATIONS.
A CUSTOMER IN ITALY REPORTED FALSE SUSCEPTIBLE BENZYLPENICILLIN AND QUINUDALFOPRISTIN RESULTS FOR ENTEROCOCCUS FAECALIS ATCC 29212 WHEN TESTED WITH THE VITEK 2 AST-P586 TEST KIT. THERE IS NO INDICATION OR REPORT FROM THE HOSPITAL TO BIOMERIEUX THAT THE DISCREPANT RESULT LED TO ANY ADVERSE EVENT RELATED TO ANY PATIENT'S STATE OF HEALTH. THE (B)(6) RESULT IS NOT DIRECTLY ASSOCIATED WITH ANY PATIENT. CULTURE SUBMITTALS HAVE BEEN REQUESTED BY BIOMERIEUX FOR INTERNAL INVESTIGATION. AN INTERNAL BIOMERIEUX INVESTIGATION WILL BE INITIATED.
Devices
| Seq | Brand | Generic | Product Code | Manufacturer | Model | Lot | UDI-DI |
|---|---|---|---|---|---|---|---|
| 733851 | VITEK 2 GRAM-POSITIVE ANTIMICROBIAL SUSCEPTIBILITY TEST AST-P586 TEST KIT | VITEK 2 AST-P586 CARD | LON | BIOMERIEUX, INC | 366359910 |
Patients
| Seq | Age | Sex | Outcome | Treatment |
|---|---|---|---|---|
| 1 |